Drugs / lactobacillus LS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06936137 | Apr 2025 → Jun 2026 overdue | acquired hypothalamic obesity | Ain Shams University | Recruiting | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT06074094 | Sep 2021 → Dec 2022 | NAFLD1 | Ain Shams University | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lactobacillus LS | “Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients” NCT06074094 ↗ |
| Modality | Other / unclassified | “Probiotic supplementation (Lacteol fort 10 billion) which contains culture medium and lactobacillus LS as active ingredients” NCT06936137 ↗ |
| Route | Oral | “was administered in the form of oral sachets once daily for 12 weeks.” NCT06074094 ↗ |